irinotecan has been researched along with Anoxemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, C; Lu, W; Zhang, Q | 1 |
| Warfel, NA | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Chang, LL; Dai, XY; Gai, RH; He, QJ; Wang, DD; Yang, B; Zhou, TY; Zhu, DF; Zhu, H; Zhuang, LH | 1 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Cao, Y; Desjardins, A; Dewhirst, MW; Friedman, HS; Herndon, JE; Marcello, JE; McLendon, RE; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
1 review(s) available for irinotecan and Anoxemia
| Article | Year |
|---|---|
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
1 trial(s) available for irinotecan and Anoxemia
| Article | Year |
|---|---|
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Female; Humans; Hypoxia; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Proportional Hazards Models; Radiography; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
5 other study(ies) available for irinotecan and Anoxemia
| Article | Year |
|---|---|
Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Ether; Humans; Hypoxia; Irinotecan; Methods; Mice; Microsomes, Liver; Prodrugs; Structure-Activity Relationship | 2017 |
Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.
Topics: Cell Death; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Humans; Hypoxia; Irinotecan; Piperazines; Pyridines | 2017 |
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Phosphoproteins; Protein Transport; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |